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Aims: High-risk subjects with elevated C-reactive protein (CRP) are at high risk for cardiovascular events and
frequently require potent statins or combined lipid-lowering therapy to achieve lipid targets and decrease in-
ﬂammation. Our study aimed at evaluating the effects of three lipid-modifying therapies on LDL-cholesterol,
CRP levels and markers of cholesterol absorption and synthesis.
Main methods: A prospective intervention study was performed in high cardiovascular risk individuals receiv-
ing atorvastatin 10 mg daily for four weeks. Those with CRP ≥ 2.0 mg/L were randomized to another
four-week treatment period with atorvastatin 40 mg, ezetimibe 10 mg or the combination of atorvastatin
40 mg / ezetimibe 10 mg. Lipids, markers of cholesterol absorption (campesterol and β-sitosterol), and syn-
thesis (desmosterol), as well as CRP were quantiﬁed at baseline and end of study.
Key ﬁndings: One hundred and twenty two individuals were included. Atorvastatin alone or combined with
ezetimibe reduced both LDL-cholesterol and CRP (P b 0.002 vs. baseline; Wilcoxon); ezetimibe did not mod-
ify CRP. Ezetimibe-based therapies reduced absorption markers and their ratios to cholesterol (P b 0.0001 vs.
baseline, for all; Wilcoxon), whereas atorvastatin alone increased campesterol/cholesterol and β-sitosterol/
cholesterol ratios (P b 0.05 vs. baseline; Wilcoxon). In addition, ezetimibe also increased desmosterol and
desmosterol/cholesterol ratio (P b 0.0001 vs. baseline; Wilcoxon).
Signiﬁcance: These results contribute to understanding the link between cellular cholesterol homeostasis, in-
ﬂammation and lipid-modifying therapies. Our ﬁndings highlight the broader beneﬁt of combined therapy
with a potent statin and ezetimibe decreasing inﬂammation, and preventing increase in cholesterol biosyn-
thesis, an effect not observed with ezetimibe alone.© 2013 Elsevier Inc. Open access under the Elsevier OA license.Introduction
High-risk patients require intensive lipid-modifying therapy to at-
tain LDL-cholesterol goals (Cholesterol Treatment Trialists' CTT Col-
laboration et al., 2010). Statins are ﬁrst-line lipid-lowering option,
but combination with ezetimibe is often required to provide greater
LDL-cholesterol reductions (Davis and Veltri, 2007; Catapano et al.,
2006). Meta-analyses of statin trials have clearly demonstrated the
beneﬁcial effects of these drugs in reducing cardiovascular outcomes
with a net beneﬁt proportional to the magnitude of LDL-cholesterol
reduction (Cholesterol Treatment Trialists' CTT Collaboration et al.,
2010). Addition of ezetimibe, a cholesterol absorption inhibitor, to aand Vascular Biology Section,
iversity of Sao Paulo, Rua Pedro
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ardiol.br (M.C. Izar).
 vier OA license.statin, further reduces LDL-cholesterol in about 18–20% (Davis and
Veltri, 2007; Catapano et al., 2006), but can be associated with an in-
crement in endogenous cholesterol synthesis (Assmann et al., 2008).
In primary and secondary prevention studies, a signiﬁcant residual
risk can be demonstrated in spite of desirable LDL-cholesterol levels
(Ridker et al., 1998, 2005, 2009; Chan et al., 2004; Sattar et al., 2007).
Persistent inﬂammation, at least in part, seems to be related to the re-
sidual risk. In the PROVE IT-TIMI 22 trial (Ridker et al., 2005), subjects
receiving high-dose atorvastatin remained at increased risk for recur-
rence of cardiovascular events when C-reactive protein levels persisted
elevated. However, weak correlation was found between C-reactive
protein and LDL-cholesterol, thus suggesting that other mechanisms
beyond cholesterol reduction might be involved.
By blocking the endogenous cholesterol synthesis, statins increase
intestinal absorption of sterols, both cholesterol and plant sterols
(Miettinen and Gylling, 2003; Miettinen et al., 2003; Miettinen and
Gylling, 2009), whereas ezetimibe is capable of preventing the in-
crease in intestinal sterols absorption, but increases the endogenous
cholesterol synthesis (Assmann et al., 2008).
Table 1
Baseline clinical characteristics of the study population, by group.
Characteristic Atorvastatin Ezetimibe Atorva/ezetimibe P-value
40 mg 10 mg 40 mg/10 mg
N = 45 N = 40 N = 37
Age, years, median (IQR) 60 (5–65) 61 (56–65) 65 (57–71) 0.020a
Male gender, n (%) 21 (47) 24 (57) 15 (41) 0.638
CHD, n (%) 30 (67) 27 (66) 31 (84) 0.142
High-risk conditionb, n (%)
CHD or CHD risk equivalent 41 (91) 34 (83) 37 (100) 0.031c
FRS >20% 4 (9) 6 (17) 0 (0)
Smokers, n (%)
Past 6 (13) 10 (25) 5 (13) 0.554
Current 7 (16) 7 (17) 5 (13)
Non-smokers 31 (71) 23 (58) 27 (74)
Hypertension, n (%) 43 (95) 38 (95) 34 (91) 0.764
Diabetes, n (%) 20 (44) 17 (41) 16 (43) 0.721
Body weight, kg, mean (SD) 78 (13) 79 (16) 73 (11) 0.129
Body mass index, kg/m2, median (SD) 29.8 (4.3) 29.7 (5.2) 28.8 (4.2) 0.556
Waist circumference, cm, mean (SD) 99.9 (8.7) 99.6 (11.0) 96.7 (9.1) 0.258
Hip circumference, cm, mean (SD) 106 (9) 105 (8) 104 (9) 0.663
Systolic blood pressure, mmHg, mean (IQR)d,e 135 (114–143) 130 (120–144) 133 (120–148) 0.464
Diastolic blood pressure, mmHg, median (IQR)d,e 72 (66–82) 76 (66–84) 71 (67–81) 0.916
Heart rate, bpm, mean (SD)a 65 (9) 65 (12) 67 (11) 0.762
Categorical variables expressed as n (%); numerical variables presented as mean (SD) or median (IQR), as appropriate. Comparisons between groups used Chi-square or ANOVA–
Tukey.
P b 0.05
CHD, coronary heart disease; FRS, Framingham risk score; IQR, interquartile range; SD, standard deviation.
a Atorvastatin 40 mg/Ezetimibe 10 mg > Atorvastatin 40 mg.
b High-risk condition deﬁned by NCEP/ATPIII16.
c Atorvastatin 40 mg/Ezetimibe 10 mg > Ezetimibe 10 mg.
d Systolic and diastolic blood pressure, and heart rate are the average of 3 measurements with 2 min apart.
e Log-transformed variables for comparisons.
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were associated with reduction in cardiovascular disease risk and, in
contrast, absorptionmarkerswere associatedwith a two-fold increased
risk (Matthan et al., 2009).
Despite the wide use of ezetimibe, an inhibitor of intestinal cho-
lesterol absorption, in clinical practice, the beneﬁcial effect of this
lipid-modifying drug on cardiovascular events remains controversial
(Rossebø et al., 2008; Kastelein et al., 2008).
Therefore, to better understand themechanisms involved in the per-
sistent high cardiovascular risk of subjectswith elevated C-reactive pro-
tein levels, but low LDL-cholesterol levels following lipid lowering
therapy, we examined the effects of different lipid-modifying regimens
on C-reactive protein levels, markers of cholesterol absorption and
synthesis.
Materials and methods
Design and study population
A prospective, randomized, open label study, with three parallel
arms and blinded endpoints was performed. Patients were recruited
from the outpatient unit of dyslipidemias of the Federal University of
Sao Paulo from January 2011 to April 2012.The study protocol conforms
to the ethical guidelines of the 1975 Declaration of Helsinki as reﬂected
in a priori approval by the institution's human research committee
(Comitê de Ética em Pesquisa da Universidade Federal de São Paulo, São
Paulo, SP, Brazil, #1841/2011). The protocol design and procedures
were explained to all patients prior to inclusion, and they signed a vol-
untary written informed consent for the participation in this study. This
procedure is approved by our ethics committee.
Eligible patients were men and women, 30 to 75 years, at high risk
for coronary heart disease, characterized by at least one of the following
conditions: established coronary heart disease or equivalent (NCEP III,
2001); diagnosis of type 2 diabetes; or those whose Framingham
risk score was > 20%. Subjects should be at statin therapy to attainLDL-cholesterol levels below 100 mg/dL and hs-CRP ≥ 2.0 mg/L prior
to inclusion (NCEP III, 2001). Patients with unstable coronary or non-
coronary conditions during the three months preceding recruitment,
those with any planned revascularization procedure, or any known in-
ﬂammatory non-cardiovascular condition (infections, chronic inﬂam-
matory diseases, or neoplasms) that might increase C-reactive protein
were not included (Glynn et al., 2009). Other exclusion criteria were
liver, renal or gastrointestinal disease, uncontrolled metabolic disor-
ders, or other condition that might affect the tolerability or safety of
the treatments. Exclusion criterion during the studywas low adherence
(less than 85%) to the lipid-lowering regimen. Three-hundred and
thirty-two subjects were screened. After the 4-week run-in period
with atorvastatin 10 mg, one-hundred and twenty-two patients were
eligible, were randomized and completed the study protocol. Screen
failures were mainly due to low C-reactive protein levels (b2.0 mg/L)
in the run-in phase. The major characteristics of this study population
are presented in Table 1.
After an initial clinical evaluation, eligible patients had prior lipid-
lowering therapy discontinued, received nutrition counseling, in
accordance with the NCEP/ATP III guidelines (NCEP III, 2001), and
simultaneously initiated a 4-week run-in period with atorvastatin
10 mg, to conform to guidelines for high-risk patients and to homog-
enize the sample at baseline. Baseline blood samples were obtained at
the end of the run-in period for laboratory analyses. After conﬁrming
the eligibility criteria, patients were randomized to receive atorva-
statin 40 mg, ezetimibe 10 mg or combination of atorvastatin 40 mg
plus ezetimibe 10 mg daily for another 4-week period. Lifestyle
changes were reinforced and adherence to the study drugs was eval-
uated at each visit. Study design and procedures are shown in Fig. 1.
Study drugs
Atorvastatin (Lipitor ®, IPR Pharmaceuticals, Porto Rico) and
ezetimibe (Zetia®, Schering-Plough Products, Las Piedras, Porto Rico)
were provided by Pﬁzer and Merck Co, respectively.
Fig. 1. Study design and procedures. Patients with CHD or CHD risk equivalent on previous statin treatment and with LDL-cholesterol b100 mg/dL and hs-CRP ≥ 2.0 mg/L were selected.
Those whomet eligibility criteria initiated a 4-week run-in periodwith atorvastatin 10 mg. Baseline blood samples were obtained at the end of the run-in period for biochemistry, lipids,
hs-CRP, and sterols. If hs-CRP > 2.0 mg/L they were randomized to receive atorvastatin 40 mg, ezetimibe 10 mg or combination of atorvastatin 40 mg plus ezetimibe 10 mg daily for
another 4-week period. Biochemistry, lipids, hs-CRP, and sterols were collected at the end of study. CHD, coronary heart disease; hs-CRP, high-sensitivity C-reactive protein.
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Lipids and biochemistry
Biochemical analyses were performed in samples obtained after a
12-hour fasting period according to the study protocol, and they were
assayed in a central laboratory of our university. Serum total cholester-
ol, HDL-cholesterol, and triglycerides were determined by automated
methods (Advia 2400, Siemens Healthcare Diagnostics, Tokyo, Japan).
LDL-cholesterol was calculated using the Friedewald formula when tri-
glycerides were below 400 mg/dL (Friedewald et al., 1972). Glycated
hemoglobin was assayed by high-performance liquid chromatography
(Tosho G2, Tosho Inc., Tokyo, Japan); high-sensitivity C-reactive protein
(hs-CRP) was determined by nephelometry (Array 360 CE/AL, Beckmann
Coulter, Inc. Brea, CA, USA). Alanine aminotransferase (ALT), aspartate
aminotransferase (AST), gamaglutamil transpeptidase (GGT), creati-
nine and creatinekinase (CK), were assayed by automated techniques
(Advia 2400, Siemens Healthcare Diagnostics, Tokyo, Japan). Thyroid-
stimulating hormone (ultrassensitivity radioimmunoassay technique,
TSH) was determined by automated technique.
Campesterol, β-sitosterol and desmosterol
For the quantiﬁcation of plasma levels of β-sitosterol and campesterol
(markers of sterol absorption), as well as for desmosterol (precursor of
endogenous cholesterol synthesis), ultra-performance liquid chroma-
tography (UPLC) and mass spectrometry (MS) were employed, as pre-
viously reported (Kasmas et al., 2012; Ramos et al., 2011). Brieﬂy, the
method consisted of liquid-liquid extraction followed by separation in
the UPLC system and detection with an atmospheric pressure chemical
ionization (APCI) ion source mass spectrometer operating on “singleion monitoring” for each sterol (β-sitosterol, campesterol, and
desmosterol). The MS system (Quattro Premier-XE, Waters Co., UK)
was adjusted to monitor single ions formed by an APCI ion source. The
sterols were detected as their free forms, i.e., non-esteriﬁed, with the
ions being monitored with a mass to charge ratio (m/z) of 367.30 for
desmosterol, 397.25 for β-sitosterol, and 383.60 for campesterol. The
levels of compounds were determined by comparison of peak response
against a calibration curve, ranging from 0.5 μg/mL to 10.0 μg/mL. Sam-
ples presenting levels higher than 10.0 μg/mL were diluted to compare
with calibration levels. Absolute values of plasma sterols were reported
as μg/mL. As these sterols are transported by lipoproteins (Miettinen et
al., 1990), absolute values of sterols were corrected for total plasma
cholesterol and reported as their ratios to cholesterol, and expressed
as μg/mg of cholesterol.
Statistical analysis
Categorical variables are presented as n (%), and compared by
Pearson's Chi square test. Numerical variables are expressed as mean
(standard deviation, SD) or median (interquartile range, IQR). Continu-
ous variables were tested for distribution of normality by Kolmogorov–
Smirnov test. Variables with non-Gaussian distribution were log-
transformed for comparisons. For between-groups comparisons
ANOVA–Tukey test was used; for within-group comparisons, the Stu-
dent's paired t-test was employed. To compare non-cholesterol sterols,
non-parametric tests were used (Kruskal–Wallis for between-groups
comparisons and Wilcoxon, for within-group comparisons).
Percent changes in selected parameters were tested by Kruskal–
Wallis test. Comparisons of selected variables according to diabetes
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correlation tests were performed. Statistical signiﬁcance was set at
a P-value b 0.05. All analyses were made using the SPSS 17.0 for
Windows (SPSS Inc, Chicago, IL).
Results
Study population
Clinical characteristics of the study population show that patients
were comparable regardingmost of the baseline characteristics, exclud-
ing age. Subjects allocated to atorvastatin 40 mg/ezetimibe 10 mgwere
slightly older than those assigned to atorvastatin 40 mg. Forty percent
of the subjects presented diabetes mellitus. Other characteristics are
presented in Table 1.
Laboratory parameters
Baseline samples obtained after a run-in period with atorvastatin
have shown that groups were comparable regarding laboratory param-
eters. Lipids were similar at baseline, andmedian LDL-cholesterol levels
were b100 mg/dL. In addition, after a 4-week run-in period receiving
atorvastatin 10 mg, median levels of hs-CRP were above 4.0 mg/L in
all treatment arms. Other laboratory parameters are presented in
Table 2.
Four-week treatment with atorvastatin 40 mg/ezetimibe 10 mg
resulted in greater decrease in total and LDL-cholesterol than in
other groups. Other laboratory variables were comparable at this
time point (Table 3).
Atorvastatin 40 mg and the combination of atorvastatin 40 mg
plus ezetimibe 10 mg reduced total- and LDL-cholesterol and hs-CRP.
Treatment with ezetimibe 10 mg increased LDL-cholesterol levels,
when compared with atorvastatin 10 mg, and did not modify hs-CRP
(Table 3).
Campesterol, β-sitosterol and desmosterol were comparable at
baseline. Ratios of these sterols to cholesterol were also similar among
groups after a run-in period with atorvastatin 10 mg (Table 4).
At the end of study, markers of sterols absorption (plasma
campesterol and β-sitosterol) and their ratios to cholesterol were
lower in ezetimibe 10 mg when compared with atorvastatin 40 mg or
atorvastatin 40 mg/ezetimibe 10 mg; these markers were lower in ator-
vastatin 40 mg / ezetimibe 10 mg than in atorvastatin 40 mg alone. InTable 2
Baseline laboratory variables, obtained after a run-in period with atorvastatin 10 mg, by gr
Variable Atorvastatin 40 mg
N = 45
Total cholesterol, mg/dL, median (IQR)a 175 (147–187)
HDL-cholesterol, mg/dL, median (IQR)a 44 (37–52)
LDL-cholesterol, mg/dL, median (IQR)a 89 (71–106)
Triglycerides, mg/dL, median (IQR)a 158 (101–217)
Glucose, mg/dL, median (IQR)a 108 (97–115)
HbA1c, mg/dL, median (IQR)a 6.20 (5.90–6.55)
AST, IU/L, median (IQR)a 22 (19–27)
ALT, IU/L, mean (IQR)a 23 (18–33)
GGT, IU/L, mean (IQR)a 41 (25–57)
CK, IU/L, median (IQR)a 128 (80–178)
hs-CRP, mg/L, median (IQR)a 4.50 (2.80–6.73)
Creatinine, mg/dL, median (IQR)a 0.83 (0.74–0.99)
TSH, μUI/mL, median (IQR)a 2.09 (1.34–3.10)
Red blood cells, 106/mm3, mean (SD) 4.81 (0.40)
Leukocytes, 103/mm3, mean (SD) 7380 (1914)
Platelets, 103/mm3, mean (SD) 269110 (64758)
Numerical variables presented as mean (SD) or median (IQR), as appropriate. Comparisons
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Atorva, atorvastatin; CK, cr
high-sensitivity C-reactive protein; IQR, interquartile range; TSH, thyroid-stimulating horm
a Log-transformed variables for comparisons.addition, desmosterol plasma levels and desmosterol/cholesterol ratio
were higher in ezetimibe group, when compared with other groups
(Table 4).
Ezetimibe-based therapies reduced absorptionmarkers and their ra-
tios to cholesterol (P b 0.0001 vs. baseline, for all; Wilcoxon), whereas
atorvastatin alone increased campesterol/cholesterol and β-sitosterol/
cholesterol ratios (P b 0.05 vs. baseline; Wilcoxon). In addition,
ezetimibe also increased desmosterol and desmosterol/cholesterol
ratio (P b 0.0001 vs. baseline; Wilcoxon) (Table 4).
Percent changes in lipid parameters, hs-CRP, and in markers of
cholesterol absorption and synthesis are presented in Supplementary
Table 1, and Figs. 1 and 2. Percent change in campesterol and
β-sitosterol differed in ezetimibe and atorvastatin/ezetimibe vs.
atorvastatin group, whereas changes in desmosterol plasma levels dif-
fered in ezetimibe vs. atorvastatin and atorvastatin/ezetimibe.
No correlation between values of LDL-cholesterol and markers of
cholesterol absorption and synthesis were observed both at baseline
and end of study (Fig. 3). High-sensitivity C-reactive protein levels
did not correlate with campesterol or β-sitosterol both at baseline
and end of study. Desmosterol levels were inversely correlated with
C-reactive protein at baseline and end of study (rho = −0.15, P =
0.046, and rho = −0.36, P = 0.036, Spearman's correlation test).
As forty percent of subjects had diabetes mellitus, percent changes
in selected parameters were tested. No differences in changes in lipid
parameters were observed between diabetic and non-diabetic subjects,
in all groups (data not shown). In subjects receiving atorvastatin 40 mg,
percent changes in campesterol (P = 0.046 vs. non-diabetic) and
β-sitosterol (P = 0.015 vs. non-diabetic) were greater in thosewithout
diabetes compared with diabetic individuals (Supplementary Table 2).
Discussion
Our study demonstrated that in high-risk patients with acceptable
LDL-cholesterol levels, but presenting high levels of hs-CRP, the lipid
lowering strategy may produce different effects on inﬂammation de-
crease and in sterols metabolism. Thus, the choice of the drugs might
take into account other parameters beyond LDL-cholesterol targets.
These aspects seem important since no correlation between LDL-
cholesterol reduction and hs-CRP decrease was obtained in other
study (Ridker et al., 2009).
We have chosen atorvastatin, an effective statin with relatively long
half- life, in order to counter balance the stimulus for endogenousoup.
Ezetimibe 10 mg Atorva/Ezetimibe 40/10 mg
N = 37
P-value
N = 40
160 (139–195) 170 (147–209) 0.740
44 (38–53) 47 (41–53) 0.669
82 (72–114) 94 (75–117) 0.422
137 (83–175) 126 (112–174) 0.303
102 (94–113) 105 (95–123) 0.328
6.30 (5.75–7.00) 6.30 (5.93–6.75) 0.867
22 (21–27) 23 (19–27) 0.982
23 (19–34) 23 (17–30) 0.738
32 (25–49) 37 (23–64) 0.744
122 (81–197) 104 (75–147) 0.390
4.20 (2.60–6.50) 5.05 (2.42–8.98) 0.366
0.92 (0.75–1.12) 0.92 (0.78–1.06) 0.645
1.54 (1.11–2.94) 1.57 (1.24–3.00) 0.180
4.95 (0.55) 4.81 (0.40) 0.270
7540 (1670) 7710 (2308) 0.754
254000 (55341) 259500 (60273) 0.507
between groups used ANOVA–Tukey.
eatinekinase; GGT, gamaglutamil transpeptidase; HbA1c, glycated hemoglobin; hs-CRP,
one; SD, standard deviation.
Table 3
Laboratory variables, obtained after a 4-week treatment period, by group.
Variable Atorvastatin 40 mg
N = 45
Ezetimibe 10 mg
N = 40
Atorva/ezetimibe
N = 37
P-value
between groups
P-value
vs. baseline
P-value
vs. baseline
P-value
vs. baseline
Atorva group Eze group Atorva/Eze group
Total cholesterol, mg/dL, median (IQR)a 147 (130–174) 185 (161–205) 133 (109–161) b0.0001b b0.0001c b0.0001d b0.0001c
HDL-cholesterol, mg/dL, median (IQR)a 43 (39–52) 46 (40–52) 48 (39–54) 0.781 0.525 0.108 0.474
LDL-cholesterol, mg/dL, median (IQR)a 74 (59–95) 105 (94–123) 62 (48–75) b0.0001b 0.001c b0.0001d b0.0001c
Triglycerides, mg/dL, median (IQR)a 128 (90–166) 129 (87–182) 100 (77–143) 0.037e b0.0001c 0.075 b0.0001c
glucose, mg/dL, median (IQR)a 105 (99–125) 103 (93–116) 102 (95–121) 0.573 0.403 0.797 0.210
HbA1c, mg/dL, median (IQR)a 6.20 (5.90–6.70) 6.30 (5.80–6.80) 6.35 (5.93–6.88) 0.730 0.203 0.767 0.368
AST, IU/L, median (IQR)a 23.5 (20.3–29.8) 23.0 (21.0–25.0) 27.0 (20.5–32.0) 0.412 0.230 0.620 0.008d
ALT, IU/L, mean (IQR)a 27.0 (22.3–33.7) 26.0 (21.0–33.0) 24.0 (19.5–33.0) 0.454 0.082 0.187 0.042d
GGT, IU/L, median (IQR)a 41.0 (24.3–53.7) 35.0 (22.0–57.0) 40.0 (21.0–59.5) 0.887 0.793 0.447 0.176
CK, IU/L, median (IQR)a 135 (81–210) 123 (83–190) 109 (79–160) 0.420 0.164 0.648 0.116
hs-CRP, mg/L, median (IQR)a 3.00 (2.03–6.18) 4.10 (2.70–5.60) 2.10 (1.10–6.15) 0.082 0.001c 0.436 0.002c
Creatinine, mg/dL, median (IQR)a 0.85 (0.74–1.02) 0.87 (0.73–1.02) 0.89 (0.76–1.02) 0.387 0.578 0.259 0.645
TSH, μUI/mL, median (IQR)a 1.84 (1.44–2.97) 1.92 (1.26–2.64) 1.83 (1.30–3.23) 0.778 0.080 0.047d 0.552
Red blood cells, 106/mm3, mean (SD) 4.82 (0.38) 4.91 (0.49) 4.81 (0.41) 0.555 0.877 0.624 0.826
Leukocytes, 103/mm3, mean (SD) 6910 (1549) 7240 (1875) 8050 (2458) 0.036f 0.032c 0.380 0.344
Platelets, 103/mm3, mean (SD) 263230 (63676) 265030 (66432) 258280 (65298) 0.899 0.295 0.024d 0.929
Numerical variables presented as mean (SD) or median (IQR), as appropriate. Comparisons between groups used ANOVA–Tukey. Comparisons within group (vs. baseline) used
paired T-test.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Atorva, atorvastatin; CK, creatinekinase; Eze, ezetimibe; GGT, gamaglutamil transpeptidase; HbA1c, glycated
hemoglobin; hs-CRP, high-sensitivity C-reactive protein; IQR, interquartile range; TSH, thyroid-stimulating hormone; SD, standard deviation.
a Log-transformed variables for comparisons.
b Atorvastatin 40 mg and atorvastatin 40 mg/ezetimibe 10 mg b ezetimibe 10 mg and atorvastatin 40 mg/ezetimibe 10 mg b atorvastatin 40 mg.
c Baseline > end of study.
d Baseline b end of study.
e Ezetimibe > Atorvastatin 40 mg/Ezetimibe 10 mg.
f Atorvastatin 40 mg b atorvastatin 40 mg/ezetimibe 10 mg.
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was considered an appropriate strategy to reduce both LDL-cholesterol
levels and hs-CRP.
The study shows that the ineffectiveness of ezetimibe alone to
achieve lipid targets or decrease hs-CRP levels was probably related
to the increase in endogenous cholesterol synthesis observed with
this drug.
Atorvastatin can increase sterols absorption in the intestine by
two mechanisms: the blockade of cholesterol synthesis (SmahelováTable 4
Values of campesterol, β-sitosterol and desmosterol, and their ratios to cholesterol, at base
Variable Atorvastatin 40 mg
N = 45
Ezetimibe 10 mg
N = 40
Atorvastatin/ez
N = 37
Campesterol, μg/mL (IQR)
Baseline 0.42 (0.30–0.73) 0.45 (0.31–0.61) 0.54 (0.34–0.93
End of study 0.46 (0.36–0.71) 0.17 (0.12–0.29) 0.33 (0.18–0.43
ratio to cholesterola
Baseline 0.25 (0.18–0.44) 0.28 (0.18–0.35) 0.29 (0.20–0.54
End of study 0.34 (0.24–0.46) 0.10 (0.08–0.15) 0.25 (0.19–0.37
β-sitosterol, μg/mL (IQR)
Baseline 0.34 (0.25–0.48) 0.37 (0.29–0.53) 0.57 (0.27–0.73
End of study 0.38 (0.29–0.61) 0.18 (0.14–0.30) 0.29 (0.17–0.47
Ratio to cholesterola
Baseline 0.19 (0.16–0.36) 0.22 (0.16–0.29) 0.30 (0.21–0.46
End of study 0.25 (0.18–0.40) 0.10 (0.07–0.14) 0.21 (0.15–0.36
Desmosterol, μg/mL (IQR)
Baseline 0.11 (0.02–0.14) 0.13 (0.00–0.16) 0.12 (0.11–0.16
End of study 0.11 (0.00–0.14) 0.21 (0.14–0.27) 0.11 (0.00–0.14
Ratio to cholesterole
Baseline 0.06 (0.00–0.08) 0.06 (0.00–0.09) 0.07 (0.00–0.08
End of study 0.07 (0.00–0.09) 0.08 (0.07–0.13) 0.06 (0.00–0.10
Values expressed as median (IQR).
IQR, interquartile range.
a Baseline > end of study.
b Ezetimibe 10 mg b atorvastatin 40 mg and atorvastatin 40 mg/ezetimibe 10 mg; atorv
c Baseline b end of study.
d Atorvastatin 40 mg > ezetimibe 10 mg.
e Ratios are expressed as μg/mg cholesterol.
f Ezetimibe 10 mg > atorvastatin 40 mg and atorvastatin 40 mg/ezetimibe 10 mg.et al., 2005), causing up regulation of the NPC1L1 expression, and
the interference with the ABCG5/G8 transporters, decreasing the
extrusion of cholesterol and phytosterols to the intestine lumen
(Kajinami et al., 2004). Therefore, the combined use of ezetimibe in
subjects treated with atorvastatin appears to be a very interesting
lipid-lowering approach. In fact, previous studies of our group have
demonstrated that statins, especially those with short half-life, in-
crease cholesterol absorption and do not reduce cholesterol synthesis
effectively (Kasmas et al., 2012).line and end of study, by group.
etimibe P-value
(between group)
P-value
(atorvastatin)
P-value
(ezetimibe)
P-value
(atorvastatin/eze)
) 0.635 0.164 b0.0001a b0.0001a
) b0.0001b
) 0.697 0.014c b0.0001a b0.0001a
) b0.0001b
) 0151 0.082 b0.0001a b0.0001a
) b0.0001d
) 0.159 0.007c b0.0001a 0.005a
) b0.0001d
) 0.177 0.583 b0.0001c 0.077
) b0.0001f
) 0.878 0.852 b0.0001c 0.675
) 0.008f
astatin 40 mg/ezetimibe 10 mg b atorvastatin.
Fig. 2. Box-plots representing percent changes in LDL-cholesterol levels (A) and hs-C-reactive protein (B) in groups, according to treatment. Boxes represent median, 25th and 75th
percentiles and whiskers are extreme values. (A) Percent change in LDL-cholesterol differed in ezetimibe vs. atorvastatin and atorvastatin/ezetimibe; percent change in
LDL-cholesterol differed in atorvastatin vs. atorvastatin/ezetimibe (P b 0.0001, Kruskal–Wallis); (B) No differences in percent changes in hs-C-reactive protein between groups
were observed (P = 0.644, Kruskal–Wallis).
850 S.P. Barbosa et al. / Life Sciences 92 (2013) 845–851High-risk patients often need combined therapy to achieve LDL-
cholesterol goals, and persistent inﬂammation is a condition that is
not completely reversed when statins are given (Ridker et al., 2008,
2009). Although there is no formal indication for statins aiming at low-
ering hs-CRP, studies have demonstrated a beneﬁcial effect of these
drugs (Ridker et al., 2008, 2009). Part of these effects are related to de-
crease in cholesterol synthesis that leads to lower expression of small
G-proteins that participate in the signaling cascade for transcription of
pro- and anti-inﬂammatory genes, and increases nitric oxide biosynthe-
sis, with a net beneﬁt on atherosclerosis (Landmesser et al., 2005; Zhou
and Liao, 2010). In this study, a reduction of ~50% from the baseline
hs-CRP levels was achievedwith atorvastatin or atorvastatin/ezetimibe,
but not with ezetimibe alone, what has been highlighted in other stud-
ies (Liu et al., 2009; Ye et al., 2012; Rudofsky et al., 2012).
Previous studies have indicated an increased absolute event risk in
patients in primary or secondary prevention of cardiovascular disease
if hs-CRP levels were elevated regardless the LDL-cholesterol levels
(Ridker et al., 1998, 2005; Sattar et al., 2007). Ezetimibe acts through
inhibiting the Niemann–Pick C1 Like 1 (NPC1L1) transporter at theFig. 3. Box-plots representing percent changes in campesterol (A), β-sitosterol (B) and de
campesterol and (B) β-sitosterol differed in ezetimibe and atorvastatin/ezetimibe vs. ator
ezetimibe vs. atorvastatin and atorvastatin/ezetimibe (P b 0.0001, Kruskal–Wallis).enterocyte with an important synergism with statins in reducing
LDL-cholesterol levels (Davis and Veltri, 2007). However, ezetimibe
also increases endogenous cholesterol synthesis, with a potential
harmful effect on vascular function and inﬂammation attributed to
intermediate compounds generated in the cholesterol biosynthesis
pathway (Rho, Rac, and the downstream target Rho-kinase), which
are down regulated by statins (Liu et al., 2009; Ye et al., 2012;
Rudofsky et al., 2012; 28).
The increase in endogenous cholesterol synthesis precursor,
desmosterol, observed with this drug may be an explanation for the
lack of efﬁcacy of ezetimibe in reducing hs-CRP levels when given
alone (Thongtang et al., 2012). In fact, the augmented cholesterol
synthesis determines an increase in the expression of intermediate
compounds, such as farnesyl pyrophosphate or geranyl geranyl pyro-
phosphate, related to the translocation of small signaling proteins to
the membrane (Landmesser et al., 2005; Zhou and Liao, 2010). By
speciﬁc stimuli, these small proteins can increase the transcription
of genes related to inﬂammation and thrombosis. In addition, in-
creased activity of Rho/Rho-kinase decreases the phosphorylation ofsmosterol (C) plasma levels in groups according to treatment. (A) Percent change in
vastatin (P b 0.0001, Kruskal–Wallis); (C) Percent change in desmosterol differed in
851S.P. Barbosa et al. / Life Sciences 92 (2013) 845–851nitric oxide (NO) synthase, thus reducing NO release. Statins can in-
crease NO release due to decrease in the Rho/Rho-kinase expression,
which increases the PI 3-kinase/Akt pathway (Landmesser et al.,
2005; Zhou and Liao, 2010).
A meta-analysis explored the effects of statins, ezetimibe and their
combination on circulating non-cholesterol sterols (Descamps et al.,
2011), reinforcing our ﬁndings that statins and ezetimibe have inverse
effects on cholesterol absorption and synthesis markers, and that
when added to a statin, ezetimibe counters the compensatory increase
in cholesterol absorption induced by statins. Recently, Thongtang et al.
(2012) demonstrated that patients on high-potency statins had the
highest levels of cholesterol absorption markers and the lowest levels
of cholesterol synthesis markers, with a greater beneﬁt from addition
of ezetimibe on these markers, if further reduction of LDL-cholesterol
was needed. However, the association between markers of cholesterol
absorption and cardiovascular disease has been addressed in a system-
atic review and meta-analysis by Genser et al. (2012), without clear
evidence that moderate ﬂuctuations on plasma concentrations of
plant sterols can affect cardiovascular disease risk.
Conclusions
In summary, our results are timely and contribute to better under-
standing the link between cellular cholesterol homeostasis, inﬂamma-
tion and lipid-modifying therapies. Our ﬁndings highlight the broader
beneﬁt of combined therapy with a potent statin and ezetimibe de-
creasing LDL-cholesterol and inﬂammation, and preventing increase
in cholesterol synthesis, an effect not observed with ezetimibe alone.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.lfs.2013.02.018.
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